• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    11/4/24 4:16:21 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RXRX alert in real time by email
    SC 13G/A 1 tm2427110d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    Schedule 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No.  1)*

     

     

     

    Recursion Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Class A Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    75629V104

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    Page 2 of 8

    CUSIP No. 75629V104

     

    1

    NAME OF REPORTING PERSONS

     

    Kinnevik AB

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨      (b) ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Sweden

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    11,905,668 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    11,905,668 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,905,668(1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.3% (2)

    12

    TYPE OF REPORTING PERSON

     

    CO

     

    (1)Consists of 11,905,668 shares of the Class A Common Stock of Recursion Pharmaceuticals, Inc. (the “Issuer”) directly beneficially owned by Invik S.A. (“Invik”), which is a wholly and directly owned subsidiary of Kinnevik AB (“Kinnevik”). Kinnevik may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”)) the securities directly beneficially owned by Invik.
       
    (2)Calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act and based on an aggregate total of 273,940,019 shares of the Issuer’s Class A Common Stock outstanding as of July 31, 2024, as reported by the Issuer in its Quarterly Report filed on Form 10-Q for the period ended June 30, 2024, filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2024.

     

     

     

     

    Page 3 of 8

    CUSIP No. 75629V104

     

    1

    NAME OF REPORTING PERSONS

     

    Invik S.A.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨      (b) ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Grand Duchy of Luxembourg

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    11,905,668 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    11,905,668 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,905,668 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.3% (2)

    12

    TYPE OF REPORTING PERSON

     

    CO

     

    (1)Consists of 11,905,668 shares of the Class A Common Stock of the Issuer directly beneficially owned by Invik.
       
    (2)Calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act and based on an aggregate total of 273,940,019 shares of the Issuer’s Class A Common Stock outstanding as of July 31, 2024 as reported by the Issuer in its Quarterly Report filed on Form 10-Q for the period ended June 30, 2024, filed with the SEC on August 8, 2024.

     

     

     

     

    Page 4 of 8

    CUSIP No. 75629V104

     

    This Amendment Number 1 (this “Amendment”) amends the statement on Schedule 13G initially filed by the Reporting Persons (as defined in Item 2(a) below) on May 22, 2023 with the Securities and Exchange Commission (the “SEC”). This Amendment is being filed to confirm that the Reporting Persons have ceased to be beneficial owners of more than 5% of the registered class of the Issuer’s (defined in Item 1(a) below) equity security as of September 30, 2024.

     

    Item 1(a).Name of Issuer.

     

    Recursion Pharmaceuticals, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices.

     

    41 South Rio Grande Street

    Salt Lake City, UT 84101

     

    Item 2(a).Name of Persons Filing.

     

    Kinnevik AB (“Kinnevik”), a public company with limited liability formed under the laws of Sweden; and
    Invik S.A., a private company with limited liability formed under the laws of the Grand Duchy of Luxembourg (“Invik” and, together with Kinnevik, the “Reporting Persons”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence.

     

    The address of the principal business office of Kinnevik is:

     

    Skeppsbron 18
    SE-103 13 Stockholm
     Sweden

     

    The address of the principal business office of Invik is:

     

    51, Boulevard Grande-duchesse Charlotte
    Grand Duchy Of Luxembourg N4 1331

     

    Item 2(c).Citizenship.

     

    Kinnevik is formed under the laws of Sweden.
    Invik is formed under the laws of the Grand Duchy of Luxembourg.

     

    Item 2(d).Title of Class of Securities.

     

    Class A Common Stock, par value $0.00001 per share

     

    Item 2(e).CUSIP Number.

     

     75629V104

     

     

     

     

    Page 5 of 8

    CUSIP No. 75629V104

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d–1(b)(1)(ii)(K).
        If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:________________________________.

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

    (a) Amount Beneficially Owned:

     

      Reference to “beneficial ownership” of securities for purposes of this Amendment shall be understood to refer to beneficial ownership as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

     

      As of September 30, 2024, the Reporting Persons may be deemed to beneficially own an aggregate 11,905,668 shares of the Issuer’s Class A Common Stock. Invik is the direct beneficial owner of all of the securities described in the preceding sentence. Kinnevik is the sole stockholder of Invik and, as such, Kinnevik may be deemed to indirectly beneficially own all of the Issuer’s securities directly beneficially owned by Invik.

     

    (b) Percent of Class:

     

      As of September 30, 2024, the Reporting Persons were deemed to directly or indirectly beneficially own an aggregate 4.3% of the Issuer’s outstanding Class A Common Stock. Invik directly beneficially owns such percentage and Kinnevik is the indirect beneficial owner of the same percentage.

     

     

     

     

    Page 6 of 8

    CUSIP No. 75629V104

     

     The aforementioned percentage was calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act and based on an aggregate total of 273,940,019 shares of the Issuer’s Class A Common Stock outstanding as of July 31, 2024 as reported by the Issuer in its Quarterly Report filed on Form 10-Q for the period ended June 30, 2024, filed with the SEC on August 8, 2024.

     

     (c)Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote:

     

    Reporting Person  Number of Shares 
    Kinnevik  0 
    Invik  0 

     

      (ii) Shared power to vote or to direct the vote:

     

    Reporting Person  Number of Shares 
    Kinnevik  11,905,668 
    Invik  11,905,668 

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    Reporting Person  Number of Shares 
    Kinnevik  0 
    Invik  0 

     

      (iv) Shared power to dispose or to direct the disposition of:

     

    Reporting Person  Number of Shares 
    Kinnevik  11,905,668 
    Invik  11,905,668 

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Item 6 is not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Item 7 is not applicable.

     

     

     

     

    Page 7 of 8

    CUSIP No. 75629V104

     

    Item 8.Identification and Classification of Members of the Group.

     

    Item 8 is not applicable.

     

    Item 9.Notice of Dissolution of a Group.

     

    Item 9 is not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.141-11.

     

     

     

     

    Page 8 of 8

    CUSIP No. 75629V104

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

                       Dated:  November 4, 2024 KINNEVIK AB
       
      By: /s/ Samuel Sjostrom
      Name: Samuel Sjostrom
      Title: Chief Financial Officer
       
                      Dated:  November 4, 2024 INVIK S.A.
       
      By: /s/ Mikael Holmberg
      Name: Mikael Holmberg
      Title: Director

     

     

     

    Get the next $RXRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RXRX

    DatePrice TargetRatingAnalyst
    5/22/2023$8.00Equal-Weight
    Morgan Stanley
    3/16/2023$17.00Buy
    Needham
    9/16/2022$20.00Overweight
    KeyBanc Capital Markets
    4/18/2022$10.00Buy → Neutral
    BofA Securities
    3/4/2022$32.00 → $10.00Outperform → Market Perform
    SVB Leerink
    12/8/2021$30.00 → $32.00Outperform
    SVB Leerink
    9/21/2021$37.00Buy
    Berenberg
    8/16/2021$33.00 → $30.00Outperform
    SVB Leerink
    More analyst ratings

    $RXRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recursion to Participate in Upcoming Investor Conferences

      Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Bank of America 2025 Health Care Conference — Tuesday, May 13, 2025 JP Morgan Global Technology, Media and Communications Conference — Thursday, May 15, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.  About RecursionRecursion (NASDAQ:RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the

      5/6/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

      Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 preclinical program following a strategic, data-driven reviewPartnerships: Achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseasesPlatform and Operations: Implemented meaningful synergies and streamlined operations while maintaining capabilities, resulting in cash runway until mid 2027 SALT LAKE CITY, May 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a le

      5/5/25 6:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

      In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff.Five of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82%, however, one patient showed a substantial increase from baseline.At Week 13, 50% of patients (3 out of 6) achieved ≥1-point improvement in Spigelman stage, a measure of upper GI disease severity.The early safety profile of REC-4881 was generally consistent with that of prior MEK1/2 inhibitors; among 19 patients across Phase 1b and 2, most treatment-related adverse events were Grade 1 or 2, with Grade 3 events in 16% of patients and no Grade ≥4

      5/4/25 12:45:00 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    SEC Filings

    See more
    • SEC Form S-8 filed by Recursion Pharmaceuticals Inc.

      S-8 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/5/25 6:07:27 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Recursion Pharmaceuticals Inc.

      10-Q - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/5/25 6:02:27 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/5/25 6:01:30 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

      Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00

      5/22/23 7:50:41 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham initiated coverage on Recursion Pharmaceuticals with a new price target

      Needham initiated coverage of Recursion Pharmaceuticals with a rating of Buy and set a new price target of $17.00

      3/16/23 9:18:01 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • KeyBanc Capital Markets initiated coverage on Recursion Pharmaceuticals with a new price target

      KeyBanc Capital Markets initiated coverage of Recursion Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

      9/16/22 7:27:04 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 4:57:06 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 10:34:18 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/4/24 4:16:21 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

      Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the

      3/18/25 8:00:00 AM ET
      $DVAX
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Altitude Lab Startups Raise $154M in Capital

      SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse life science entrepreneurs in Utah by providing fully equipped laboratories, access to investors, business operations education, and a collaborative founder community.In addition, Altitude Lab awarded its inaugural Gibson Founder Fellowship to Carmen Kivisild, Ph.D., CEO and founder of Elnora AI. The fellowship provides early-career scientists with up to $150,000 in funding, scientific support, and mentorship to accelerate the growth of their sta

      2/18/25 11:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

      Dr. Secora is formerly the CFO and Executive Leader of Value Translation at Recursion Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and Chief Financial Officer. Dr Secora will lead Iambic's finance and corporate development activities, helping frame its growing pipeline and industry-leading platform to potential partners, investors, and other stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106188573/en/Michael Secora, PhD, Chief Cor

      1/6/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Financials

    Live finance-specific insights

    See more
    • Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

      Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/LYZwaVdPJidC7x259. Abo

      4/28/25 8:27:07 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

      Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://bit

      2/24/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

      REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatmentAdditional 4 patients demonstrated a best response of stable disease (SD) for up to 6 months of treatmentPlans to continue monotherapy dose escalation and initiate combination studies in 1H 2025 SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) --

      12/9/24 6:00:00 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Taylor Ben R covered exercise/tax liability with 26,571 shares, decreasing direct ownership by 3% to 842,099 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      4/3/25 4:38:14 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Li Dean Y was granted 2,268 shares, increasing direct ownership by 3% to 79,618 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      4/3/25 4:37:52 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Dar Zavain was granted 2,745 shares, increasing direct ownership by 3% to 110,877 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      4/3/25 4:37:01 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care